<?xml version="1.0" encoding="UTF-8"?>
<p id="Par57">Broadly, the clinical impact of COVID-19 on PD could occur through multiple avenues:
 <list list-type="order">
  <list-item>
   <p id="Par58">Development of COVID-19-related symptoms, particularly high fever, severe respiratory distress, coagulopathy-related syndrome, fatigue, myalgias, and related impaired stress mechanisms.</p>
  </list-item>
  <list-item>
   <p id="Par59">Worsening of pre-existing dyspnea due to respiratory distress; dyspnea may exist in up to 39% of PD patients
    <sup>
     <xref ref-type="bibr" rid="CR152">152</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par60">In acutely ill patients admitted to hospital, confusion and delirium could occur (reported in over 25% of COVID-19 hospitalized subjects out of a survey of 3500 patients)
    <sup>
     <xref ref-type="bibr" rid="CR38">38</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par61">Worsening of specific symptoms, including motor symptoms as well as non-motor issues, such as pain, anxiety, sleep disturbances and fatigue, especially with reduced access to physical therapy and counseling
    <sup>
     <xref ref-type="bibr" rid="CR45">45</xref>,
     <xref ref-type="bibr" rid="CR144">144</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par62">Social isolation and aggravation of underlying cognitive and behavioral symptoms, specifically anxiety
    <sup>
     <xref ref-type="bibr" rid="CR153">153</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par63">Possibility of post-traumatic stress disorder (PTSD) as observed in previous SARS and MERS pandemics
    <sup>
     <xref ref-type="bibr" rid="CR38">38</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par64">Increased levodopa requirement during acute admissions and need for non-oral dopaminergic therapies in some subjects with severe COVID-19 related symptoms
    <sup>
     <xref ref-type="bibr" rid="CR45">45</xref>
    </sup>.
   </p>
  </list-item>
  <list-item>
   <p id="Par65">Potential for drug interaction of over the counter cough remedies with anti-parkinsonian drugs such as monoamine oxidase inhibitors.</p>
  </list-item>
  <list-item>
   <p id="Par66">Complexity in therapeutic management related to limitations of in-person consultations and admissions to hospital
    <sup>
     <xref ref-type="bibr" rid="CR147">147</xref>
    </sup>.
   </p>
  </list-item>
 </list>
</p>
